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Introduction
The NF-κB family consists of 5 members: RelA (also known as 
p65), Rel (also known as c-Rel), RelB, p105 (processed to p50), 
and p100 (processed to p52) (1). These members form homo- and 
heterodimers that, in the resting cell, are normally held inactive 
in the cytoplasm by association with inhibitors, the IκB proteins. 
Activation of NF-κB is controlled by the IκB kinase (IKK) com-
plex that phosphorylates IκB proteins and targets them for deg-
radation, releasing the NF-κB subunits for nuclear translocation 
and transactivation of a multitude of responsive genes, including 
several inflammatory cytokines. Thus, the NF-κB pathway plays 
a crucial role in the inflammatory response of macrophages and 
lymphocytes in many inflammatory diseases.
Rheumatoid arthritis (RA) is a chronic and debilitating inflam-
matory arthropathy. Although the etiology of RA remains contro-
versial, the hallmark of the disease is characterized by inflamma-
tion of the synovial lining of diarthrodial joints, massive synovial 
proliferation, and an influx of inflammatory cells, macrophages, 
and lymphocytes through leaky angiogenic blood vessels (2–4). 
This cellular influx and synovial proliferation lead to the release 
of inflammatory cytokines and matrix-degrading enzymes, all of 
which contribute to the destruction of connective tissue, cartilage, 
and subchondral bone of the affected joints. Activated macro-
phages and lymphocytes are thus considered principal targets for 
therapy in RA. Recent understanding of inflammatory responses 
in RA has led to the development of several effective treatment 
modalities. These include a number of “biologics” aimed at inhib-
iting the action of several inflammatory cytokines, including IL-1β, 
IL-6, and TNF-α (5). Yet despite these advances, many patients 
with RA fail to respond to these new biologic agents. Moreover, 
studies have shown that around half of the initial responders even-
tually stop responding in the first year due to inefficacy or have 
to stop therapy altogether due to side effects (6). Although other 
biologic therapies, such as the JAK kinase inhibitor tofacitinib, are 
beginning to emerge (7), the complexity of RA, the heterogeneity 
of patients, and previous experience with biologics suggest that 
targeting a single receptor or cytokine pathway will not lead to a 
predictable response in patients.
We reasoned that the simultaneous interruption of several 
inflammatory cytokine pathways would lead to a higher likelihood 
of abrogating disease progression and promoting disease remis-
sion. The role of NF-κB in inflammation in general and RA in par-
ticular as a central checkpoint is well established (8–11). Accord-
ingly, in the present work, we sought to define the utility of a 
novel siRNA delivery approach using nanoparticles targeted to the 
NF-κB signaling subunit p65, which is a principal transcriptional 
regulator of the canonical NF-κB pathway (12). The nanoparticle 
construct is composed of a self-assembling peptide-siRNA com-
plex that serves to protect the siRNA from serum deactivation, 
while avoiding reticuloendothelial system uptake and delivering 
functional oligonucleotides to selected inflammatory targets (13, 
14). Key features of the complex that promote sequentially coor-
dinated endosomal uptake, endosomal lysis, and siRNA release 
depend on specific molecular features of the carrier peptide (13), 
which is derived through modification of the bee venom pep-
tide melittin (15). Selected amino acid truncations and substitu-
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injected with p5RHH siRNA nanoparticles (Figure 1A). The signal 
remained stable for at least 7 hours after injection, with gradual 
decay over time (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI75673DS1).
While previous studies have shown that i.v. administered 
free siRNAs are cleared from the system within 15 minutes (20), 
we found here that Cy5.5-labeled siRNA packaged in the p5RHH 
siRNA nanocomplexes were readily detected in the kidneys 2 hours 
after injection, and the signals persisted up to 24 hours (Figure 1B 
and Supplemental Figure 2), which suggests that siRNAs packaged 
in non-albumin-coated nanoparticles had a different clearance 
kinetics than free siRNA. In contrast, the spleen and liver — tradi-
tional clearance organs for many types of nanoparticles — did not 
sequester substantial amounts of particles (Figure 1B). Further-
more, we observed no signal from Cy5.5-labeled free siRNA in any 
organ 2 hours after i.v. administration of an equivalent load (Figure 
1B), corroborating the rapid clearance and instability of free siRNA 
compared with the more stable nanoparticle-formulated siRNA.
Because we detected no significant fluorescent signals asso-
ciated with peripheral blood or splenic phagocytes (monocytes/
macrophages and neutrophils) after p5RHH siRNA nanoparticle 
injection (Supplemental Figures 3–6), it is likely that accumula-
tion of nanoparticles represents direct delivery into the joint 
milieu without peripheral monocyte or splenic macrophage 
uptake and subsequent recruitment to the site of inflammation. 
To further explore this hypothesis, we injected day 6 arthritic 
mice with free Cy3-labeled p65 siRNA or Cy3-labeled p5RHH-
p65 siRNA nanocomplexes and examined synovial tissues for 
intracellular particle accumulation. At 2.5 hours after injection, 
we observed a number of tissue macrophages, in the immediate 
vicinity of blood vessels, that harbored high intracellular levels 
of the p5RHH-p65 siRNA nanoparticles (Figure 2). In contrast, 
scant intracellular Cy3 signal was visible in paw sections of the 
animal injected with free p65 siRNA.
tions mitigate the undesirable pore-forming capacity of peptide, 
yet retain its ability to condense siRNA and facilitate endosomal 
escape, as previously reported (13, 16). A simple mixing proce-
dure of only 10 minutes yields a complex that is small enough 
(~55 nm) to passively diffuse rapidly into inflamed tissues, where 
it is retained, yet avoids hepatic sequestration (14). Using a mouse 
model of antibody-mediated inflammatory arthritis, we found 
that anti–NF-κB peptide-siRNA self-assembling nanocomplexes 
(13, 14) effectively silenced the expression of p65 as well as a broad 
array of downstream cytokine effectors in the inflamed paws, and 
also suppressed arthritis with minimal off-target molecular effects.
Results
p5RHH siRNA nanocomplexes localize to the inflamed joints. Col-
lagen-induced arthritis (CIA) in mice is an experimental arthri-
tis model that in many ways resembles RA. Immunization of 
susceptible strains of mice with chick or bovine type II collagen 
(CII) leads to the development of anti-CII antibodies that initiate 
polyarticular arthritis (17, 18). Transfer of a combination of anti-
CII monoclonal antibodies derived from mice with CIA also leads 
to a severe arthritis accompanied by bone erosion and cartilage 
destruction (19). In this CII antibody–induced arthritis (CAIA) 
model, we injected 6- to 8-week-old male DBA1/J mice i.p. on day 
0 with a cocktail of 5 monoclonal anti-CII antibodies (1.5 mg), fol-
lowed by i.p. injection with LPS (50 μg) on day 3. Arthritis was evi-
dent consistently within 24 hours after LPS injection and persisted 
for 2–3 weeks. We administered HBSS, free Cy5.5-labeled scram-
bled siRNA or p5RHH-Cy5.5–labeled scrambled siRNA nano-
complexes (referred to herein as p5RHH siRNA nanoparticles) to 
arthritic mice on day 4 and followed particle accumulation in vivo 
after injection through whole-body fluorescence imaging (IVIS). 
Free Cy5.5-labeled scrambled siRNA and p5RHH siRNA nanopar-
ticles both localized to the inflamed joints. However, we detected 
a substantially higher level of Cy5.5 fluorescence in the mouse 
Figure 1. p5RHH siRNA nanoparticles accu-
mulate in inflamed paws. Day 4 arthritic 
mice received i.v. injection of HBSS, free 
Cy5.5-labeled scrambled siRNA (Free siRNA), 
p5RHH-Cy5.5–labeled scrambled siRNA 
nanoparticles (p5RHH NP), and in vivo fluo-
rescent images were acquired over time. (A) 
Fluorescent signals were readily detected in 
the inflamed paws of arthritic mice injected 
with free Cy5.5 siRNA and p5RHH siRNA 
nanoparticles, but not HBSS. Note the sub-
stantially higher level of fluorescence in the 
p5RHH siRNA nanoparticle–injected animal 
at 7 hours. (B) Organs and blood were col-
lected 2 hours after injection for fluorescence 
imaging. The highest signals were detected 
mainly in kidneys, while uptake in the 
reticuloendothelial system (liver and spleen) 
was markedly lower. Note that p5RHH siRNA 
nanoparticles were largely cleared from the 
circulatory system (blood) 2 hours after 
injection (far right). Pseudocolor “efficiency 
image” was used to illustrate the organ 
accumulation of Cy5.5-labeled siRNA.
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form in delivering p65 siRNA to synovial macrophages 
and suppressing their inflammatory responses. While 
free p65 siRNA also diffused into inflamed tissues, the 
low level of intracellular accumulation was insufficient to 
suppress p65 expression (Figure 4C).
In parallel with improved clinical indices and histol-
ogy, we found that joint-associated inflammatory cyto-
kine production was significantly suppressed in mice 
treated with p5RHH-p65 siRNA nanoparticles (Figure 
5A). In addition, mRNA and protein expression levels 
of p65 were specifically downmodulated in the paws of 
these animals, while those of related NF-κB family mem-
bers (p100, p105, and RelB) were preserved (Figure 5, B 
and C). Moreover, we confirmed that p65 expression in 
synovial macrophages was decreased at the single-cell 
level (Figure 5D), thus corroborating the findings above 
that p5RHH-p65 siRNA nanocomplexes targeted macrophages 
and suppressed NF-κB–dependent inflammatory response in the 
mitigation of clinical arthritis. In contrast, protein levels of p65 
and other NF-κB family members in off-target organs such as liver, 
spleen, brain, and kidneys were all relatively preserved (Figure 6). 
Taken together, these findings provide proof of concept that 
p5RHH siRNA nanoparticles targeting the NF-κB p65 subunit 
selectively silenced the gene expression in the intended organs 
(joints/synovium) and potently suppressed ongoing inflammation 
in a robust model of acute inflammatory arthropathy.
In vivo toxicity profile of p5RHH-p65 siRNA nanocomplexes. To 
examine the safety of p5RHH-p65 siRNA nanoparticles in vivo, 
we first determined their effect on hematologic parameters. Serial 
i.v. injections of p5RHH-p65 siRNA nanoparticles did not affect 
peripheral wbc counts and differentials, hemoglobin levels, or 
platelet counts (Figure 7A). Although the relatively high accumula-
tion of nanoparticles in the kidney (Figure 1B and ref. 14) was sug-
gestive of preferential renal clearance, we observed no deleterious 
effects on renal function, as reflected by normal electrolytes and 
levels of blood urea nitrogen and creatinine (Figure 7, B and C). 
Finally, we detected no changes among treatment groups in liver 
function tests (Figure 7D). These results point to a favorable toxic-
ity profile in vivo after multiple doses.
Effects of p5RHH-p65 siRNA nanocomplexes on immune respons-
es. Next we examined the effects of p5RHH-p65 siRNA nanopar-
ticles on immune cell function in nontarget organs. On day 10, 
spleens from different treatment groups were harvested, and sple-
nocytes/splenocyte subpopulations were enumerated. We noted a 
trend toward higher numbers of total splenocytes in the p5RHH-
p65 siRNA nanoparticle treatment group, perhaps reflecting less 
p5RHH-p65 siRNA nanocomplexes suppress CAIA. CAIA was 
induced as above, and on day 4 (24 hours after LPS injection), when 
early arthritis was established in all mice, animals were randomly 
divided into 3 treatment groups: HBSS control, p5RHH siRNA 
complexes, and p5RHH-p65 siRNA nanocomplexes. Nanopar-
ticles were administered i.v. serially on days 4, 5, and 6. Ankle 
thickness changes, arthritis score, and percent weight loss were 
assessed over a period of 10 days. p5RHH-p65 siRNA nanopar-
ticle treatment rapidly stabilized ankle swelling and significantly 
suppressed arthritis score, an effect that persisted until at least day 
10 (Figure 3, A–C). Administration of p5RHH siRNA nanocom-
plexes did not significantly alter arthritis progression compared 
with HBSS treatment (Figure 3, A–C). In addition, treatment with 
p5RHH-p65 siRNA nanoparticles did not adversely affect the ani-
mals’ weight loss beyond that induced by inflammation and LPS 
injection (Figure 3D). On day 10, mice that received p5RHH-p65 
siRNA nanoparticles showed an approximately 75% reduction in 
ankle thickness and 65% reduction in arthritis score compared 
with HBSS and p5RHH siRNA controls. Histologic examination of 
paws harvested on day 10 revealed that treatment with p5RHH-
p65 siRNA nanoparticles significantly attenuated the influx of leu-
kocytes to the inflamed paws, protected against bone erosion, and 
preserved cartilage integrity (Figure 3, E–H). On the other hand, 
we observed no histologic difference between animals treated 
with p5RHH siRNA nanoparticles and those injected with HBSS 
(Figure 3, E–H). Furthermore, administration of equivalent doses 
of free p65 siRNA did not alter arthritis progression or production 
of joint-associated inflammatory cytokines (TNF-α, IL-1β, IL-6, 
and MCP-1) compared with HBSS injection (Figure 4, A and B). 
These results confirmed the superiority of the p5RHH-based plat-
Figure 2. p5RHH siRNA nanoparticles target synovial 
macrophages. Day 6 arthritic mice were injected with p5RHH-
Cy3–labeled p5RHH-p65 siRNA nanoparticles (p65 NP) or free 
Cy3-labeled p65 siRNA (free p65). At 2.5 hours, mice were 
sacrificed and paws obtained for immunofluorescence study. 
In the mouse injected with p5RHH-p65 siRNA nanoparticles, 
Cy3 signal (red) colocalized (yellow in merged images) with 
synovial macrophages (Mac-3+, green). In contrast, only very low 
signal was detected in the synovial macrophages of the mouse 
injected with free p65 siRNA. DAPI (blue) stained nuclei. Some 
blood vessels (V) are outlined in white. Scale bar: 20 μm.
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and collected their plasma at 30 minutes to quantify the C3 degra-
dation product C3a as evidence of in vivo complement activation 
(22). We observed an increase in C3a levels in mice injected with 
p5RHH-p65 siRNA nanoparticles compared with HBSS-injected 
animals, whereas injection with perfluorocarbon nanoparticles 
functionalized with 50 molar percentage of N-[1-(2,3-dioleoyloxy)
propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP; ref. 
22) generated markedly higher levels of C3a (Figure 9A).
To address the potential immunogenicity of p5RHH siRNA 
nanoparticles, we measured specific antibody responses against 
both p5RHH peptide and p5RHH siRNA nanocomplexes after 3 
serial injections on days 4, 5, and 6. Sera were collected from treat-
ed animals on day 10, and IgM and IgG antibodies specific for the 
peptide or the nanocomplex were measured by ELISA-based assay 
on microtiter plates coated with p5RHH siRNA nanoparticles or 
p5RHH-p65 siRNA nanoparticles. No significant difference was 
observed among the 3 treatment groups for IgM or IgG respons-
es (Figure 9, B and C). We also measured total antibody levels in 
the treated animals and observed no elevation in total IgM or IgG 
cellular efflux from spleen to inflamed sites (joints); however, this 
difference did not reach statistical significance (Figure 8A). We 
also observed no difference in the composition of the major sple-
nocyte subpopulations, including CD4+ and CD8+ T cells, CD19+ 
B cells, NK1.1+ natural killer cells, and Foxp3+ T regulatory cells 
(Figure 8B). To further assess immune cell function after p5RHH-
p65 siRNA nanoparticle treatment, we isolated splenic CD4+ T 
cells and stimulated them ex vivo on plate-bound anti-CD3 mono-
clonal antibody. Anti-CD3–activated CD4+ T cells from different 
treatment groups proliferated equivalently and released similar 
amounts of cytokines (TNF-α, IFN-γ, IL-6, and IL-10; Figure 8, 
C–F, and Supplemental Figure 7).
We previously observed that injection of certain types of func-
tionalized nanoparticles can elicit swift complement activation, the 
intensity of which depends on the specific type of nanoparticle sur-
face functionalization (21, 22). To assess whether the interaction of 
peptide-siRNA nanoparticle complexes with the host complement 
system could lead to robust activation, we injected mice with HBSS, 
p5RHH siRNA nanoparticles, or p5RHH-p65 siRNA nanoparticles 
Figure 3. p5RHH-p65 siRNA nanotherapy suppresses inflammation in CAIA. CAIA arthritis was induced as detailed in Methods (day 3 LPS injection is indi-
cated). On day 4, mice were randomly divided into 3 treatment groups: HBSS, p5RHH siRNA nanoparticles, and p5RHH-p65 siRNA nanoparticles. Nanopar-
ticles or HBSS were administered i.v. serially on days 4, 5, and 6 (Tx). (A) Representative photographs of day 10 paws from the 3 treatment groups. (B–D) 
Change in ankle thickness (B), arthritis score (C), and percent weight loss (D) were chronicled over time. Values are mean ± SEM (n = 6–8 per group). (E) Day 
10 paws were harvested, sectioned, and stained with H&E to evaluate for the number of inflammatory cells/erosions and toluidine blue to evaluate for car-
tilage integrity. Note the intense inflammatory infiltrates in and surrounding the joint space in HBSS- and p5RHH siRNA–treated animals while joint space 
in p5RHH-p65 siRNA–treated animals was largely devoid of cellular infiltrates (left). In higher-power images, erosions (asterisks) were noted along the bone 
surface in HBSS- and p5RHH siRNA–treated animals (middle). Extensive proteoglycan depletion (arrowheads) was also noted in HBSS- and p5RHH siRNA–
treated animals (right). b, bone; js, joint space. Scale bars: 400 μm (left), 100 μm (middle), 50 μm (right). (F–H) Inflammatory infiltrates per high-power field 
(HPF; F), erosions (G), and degree of proteoglycan depletion (H) were quantified as detailed in Methods. *P < 0.05, **P < 0.01, ***P < 0.001.
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silencing might be expected to achieve the specificity that is 
lacking in small-molecule inhibitors. When coupled with a safe 
and effective delivery nanoplatform, this genetic approach may 
circumvent some of the shortcomings of small-molecule inhibi-
tors by specifically suppressing inflammation in the joints, while 
largely sparing off-target toxicities.
siRNA-based therapeutics for the treatment of inflammatory 
diseases have received increasing attention of late. Several clinical 
trials are ongoing for various diseases, including age-related mac-
ular degeneration, viral infections, respiratory disorders, and can-
cer (reviewed in ref. 24). However, the potential use of siRNA ther-
apy in RA has not progressed beyond the preclinical models. These 
studies range from local electroporation to deliver siRNA directly 
into joint tissue of arthritic mice to several studies of systemic 
delivery of liposome- or polymer-based nanoparticles delivering 
anti-cytokine or anti-cytokine receptor siRNA (25–30). Although 
these preclinical studies all showed efficacy, potential off-target 
effects and immune responses were rarely fully addressed.
levels (Figure 9D). These results suggest that, at the administered 
dose and injection schedule, these p5RHH-based nanoparticles 
did not elicit systemic adaptive immune responses.
Discussion
Here, we demonstrated that the melittin-derived p5RHH pep-
tides complexed with anti-p65 siRNA successfully and potently 
suppress ongoing experimental arthritis. Evidence gathered from 
genetic knockout mice suggests a central role for NF-κB, in partic-
ular the classical or canonical pathway controlled by p65 or p50, 
in RA and other inflammation-related pathologies (1, 8). Because 
activation of the canonical pathway results in the transactiva-
tion of a number of inflammatory mediators, including TNF-α, 
chemokines, and matrix metalloproteases, NF-κB subunit p65 
represents an attractive target in RA, especially in instances in 
which inhibition of single cytokines proves ineffective. Despite 
much interest, small-molecule inhibitor approaches have not 
been promising due to lack of specificity (23). Alternatively, gene 
Figure 4. Administration of free p65 siRNA does not suppress CAIA. Arthritis was induced as detailed in Methods (day 3 LPS injection is indicated). On 
day 4, mice were randomly divided into 2 treatment groups: HBSS and free p65 siRNA. Treatment (Tx) was administered i.v. serially on days 4, 5, and 6. (A) 
Changes in ankle thickness, arthritis score, and percent weight loss were chronicled over time. On day 10, animals were sacrificed and paws processed for 
(B) cytokine levels and (C) Western blot analysis of p65 and related NF-κB family members (p100, p105, and RelB). p100 and p105 were detected in both 
precursor and processed forms (p52 and p50, respectively). No statistical difference between treatments was noted.
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Cationic lipids and polymers have been successfully used for 
in vivo siRNA delivery in preclinical models; however, potential 
toxicities (31–33) have hindered the clinical translation of these 
platforms. Moreover, these agents tend to aggregate with serum 
proteins in vivo and often mediate robust complement activation 
with potential deleterious effects (34–36). We recently reported the 
development of an amphipathic peptide-based siRNA nanoplat-
form (13, 14) that uses a modified version of the bee venom com-
ponent melittin to transport siRNA (15). Melittin is a well-studied 
peptide with pore-forming features that derive from its ability to 
insert into lipid membranes stably through hydrophobic interac-
tions among resident membrane phospholipids interacting with its 
α-helical peptide secondary structure (16, 37, 38). Subsequent mul-
timeric oligomerization establishes a membrane pore, resulting in 
disruption and cell death. Alternatively, apoptosis may be induced 
through interactions with intracellular mitochondrial membranes, 
depending on membrane cholesterol content (39, 40).
In order to limit the immediate pore-forming potential of 
melittin, we initially modified its sequence by selective trunca-
tions to produce a shorter amphipathic cationic peptide (termed 
Figure 5. p5RHH-p65 siRNA nanoparticles downmodulate inflammatory cytokine production and the expression of p65 specifically in the joints. (A) 
Day 10 paws were homogenized, and cleared lysates were assayed for inflammatory cytokines. **P < 0.01, ***P < 0.001. (B) Paws were processed and exam-
ined for p65 and p100 mRNA expression relative to Gapdh by real-time PCR. ND, not detected. (C) Paw lysates were probed for the presence of p65, p100, 
p105, and RelB by Western blotting. The protein expression of p65 was attenuated in the paw lysates of p5RHH-p65 siRNA nanoparticle–treated animals, 
whereas expression of related NF-κB family members was relatively preserved. The analysis was repeated with a second cohort of mice treated with the 
same regimen, and similar results were obtained. (D) Day 10 paw sections were probed for macrophages (F4/80+; red) and p65 (green). DAPI (blue) stained 
nuclei. Note that p65 protein expression per single cell was decreased in the mouse treated with p5RHH-p65 siRNA nanoparticles. Scale bar: 25 μm.
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p5) that serves well as a “cargo carrier” capable of inserting rap-
idly into lipid membranes, but is substantially less lytic compared 
with native melittin (5,700% decrease; ref. 38). After uptake of the 
nanoparticles into endosomes, the residual lytic activity of the p5 
peptide enables the disruption of endosomal membrane, allow-
ing the siRNA to escape, as previously shown (14). Further modi-
fications of the peptide sequence were shown to enable numer-
ous other useful attributes, such as protected siRNA transport in 
circulation and rapid delivery to target tissues through passive 
permeation in addition to endosomal escape after pinocytotic 
uptake and concomitant rapid release of siRNA that depends on 
endosomal acidification and peptide protonation (13, 14). Avoid-
ance of liver/spleen sequestration and renal clearance also serve 
to promote more focused tissue interactions, particularly under 
conditions of inflammation and enhanced vascular permeability, 
as in cancers (14). Finally, the approach is agnostic as to the exact 
oligonucleotide sequence, and the entire complex can be formed 
within as little as 10 minutes by a simple mixing procedure that 
allows noncovalent self assembly of cationic and anionic moieties 
into ~55-nm particles ready for direct injection.
The safety of the system in these short-term applications at 
least appears promising for translation, based on the extensive 
set of studies we conducted to rule out organ, tissue, and bio-
chemical off-target effects. Initial studies suggested that 3 serial 
injections of the nanocomplexes did not elicit a specific humoral 
response. However, immunogenicity after repeated dosings of the 
nanocomplexes will require further evaluation. These observa-
tions also point to a lack of knockdown of normal levels of p65 in 
other tissues, in which physiological functioning of NF-κB would 
be expected to remain undisturbed, including innate and adap-
tive T cell–mediated immune responsiveness. The rapid entry into 
desired tissue compartments and subsequent prolonged seques-
tration may initiate through inflamed and leaky vasculature, much 
like the endothelial permeability and retention (EPR) effect pro-
posed for nanoparticle cancer localization.
In concert with primary kidney clearance, and given the 
advantageous particle sizes for the complex, the potential for 
permeation into other normal tissues appears to be minimized. 
The avoidance of liver and spleen sequestration and the ability 
to maintain normal immune responsiveness elsewhere is a par-
ticular advantage of this technology, in contrast to other systems 
that might impair immune reactivity (41), with potentially del-
eterious consequences for cancer surveillance and susceptibility 
to infectious diseases. We speculate that the lack of liver/spleen 
uptake for these types of nanoparticles may be related to their 
immediate acquisition of an albumin coating after injection, 
which might be anticipated for any nanosystem in the circula-
tion. Indeed, albumin is known to act both as a particle-stabiliz-
ing agent and as a dysopsonin, thereby avoiding liver sequestra-
tion (14). Moreover, we have shown previously that an exogenous 
albumin coating enhances transfection potential in vitro, which 
may offer another advantage for the system after interacting 
with serum proteins in vivo (13).
In summary, we have shown that the p5RHH siRNA platform 
is a potent and facile delivery system due to its self-assembling 
property. The ease with which the siRNA moiety can be switched 
out, because it is not chemically conjugated, suggests that its util-
ity can be extended to a number of therapeutic RNA candidates. In 
addition to therapeutic applications, the platform may also be used 
to interrogate pathway involvement in the pathogenesis of RA and 
other inflammatory diseases. Although we took advantage of the 
EPR effect to deliver the nanocomplexes in this study, targeting 
ligands could be added for enhanced local accumulation or cell 
interactions if the need arises. Finally, it is important to point out 
that the nanoparticle formulation is critical to the success of the 
agent, because even though free siRNA localizes to the intended 
site (inflamed joints), it exhibits no gene silencing activity. This is 
likely because siRNA packaged as p5RHH nanocomplexes gained 
access to the cell cytoplasm through micropinocytosis (14), while 
the free siRNA could not. Taken together, our results suggest that 
this platform, with its relative site-specific gene silencing activity 
combined with minimal off-target toxicities, may have real trans-
lational potential for the treatment of many inflammatory pro-
cesses beyond arthritis.
Figure 6. p65 downmodulation is specific to 
the inflamed joints. Arthritic mice were serially 
treated with HBSS, p5RHH siRNA nanopar-
ticles, or p5RHH-p65 siRNA nanoparticles 
on days 4, 5, and 6. Day 10 off-target organs 
(spleen, liver, kidney, and brain) were processed, 
and protein lysates were probed for expres-
sion of p65 and related NF-κB family members 
(p100, p105, and RelB) by Western blotting. The 
processed forms of p100 and p105 (p52 and p50, 
respectively) were only detected in spleen.
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14%) than the albumin-coated particles by dynamic light scattering 
after 40 minutes of mixing the components (13).
Arthritis induction and treatment. All mice were kept in a patho-
gen-free condition at Washington University Specialized Research 
Facility. Arthritis was induced using the collagen antibody–induced 
arthritis model (CAIA) with Arthrogen-CIA arthrogenic monoclonal 
antibody 5-clone cocktail (Chondrex). 6- to 8-week-old male DBA/1J 
mice (Taconic) were injected i.p. with 1.5 mg of the 5-clone antibody 
cocktail on day 0 and 50 μg of LPS on day 3. Starting on day 4, when 
early arthritis was established, animals received daily serial i.v. injec-
tions of p5RHH siRNA nanoparticles, p5RHH-p65 siRNA nanopar-
ticles (1 mg/kg i.v. by tail vein), or an equivalent concentration of free 
p65 siRNA for 3 consecutive days. HBSS injection served as the con-
trol. Clinical manifestations of arthritis were assessed daily on a scale 
of 0–3 (0, no swelling or erythema; 1, slight swelling or erythema; 2, 
moderate erythema and swelling in multiple digits or entire paw; 3, 
pronounced erythema and swelling of entire paw), with a maximum 
score of 12 (3 score × 4 paws) per mouse. Change from baseline in 
Methods
Preparation of p5RHH siRNA nanocomplexes. p5RHH peptide (provided 
by Genscript) was dissolved at 10 mM in DNAse-, RNAse-, and pro-
tease-free sterile purified water (Cellgro) and stored in 10-μl aliquots 
at –80°C before use. The Cy5.5-labeled scrambled siRNAs and Cy3-
labeled p65 siRNAs were ordered from Sigma-Aldrich, dissolved at 
100 μM in 1× siRNA buffer (Thermo Scientific), and stored in 10-μl 
aliquots at –80°C before use. The p5RHH siRNA nanoparticles were 
prepared by mixing equal volumes of the aforementioned p5RHH pep-
tide and siRNA at a peptide/siRNA ratio of 1:20 in HBSS with Ca2+ and 
Mg2+ (Gibco, Life Technologies) and incubated on ice for 10 minutes 
before injection (14). This preparation typically results in a nominal 
nanoparticle size of approximately 55 nm after applying a stabilizing 
albumin coating, as measured by atomic force microscopy (14), and 
zeta potentials varying from +12 to –5.5 mV and polydispersity index 
varying from 0.120 to 0.190 depending on size and the presence or 
absence of an exogenously applied albumin coating (13). We also have 
previously shown that the uncoated particles are slightly smaller (by 
Figure 7. In vivo toxicity profile of p5RHH-p65 siRNA nanoparticles. Arthritic mice were serially treated with HBSS, p5RHH siRNA nanoparticles, or 
p5RHH-p65 siRNA nanoparticles, on days 4, 5, and 6, and blood was obtained on day 10. (A) Hematologic parameters: wbc counts/differentials, hemo-
globin, and platelet counts. (B) Serum electrolytes: sodium, chloride, and potassium. (C and D) Renal (C) and liver (D) function. BUN, blood urea nitrogen. 
There was no significant difference noted among the 3 treatment groups.
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anti-mouse p65 (1:100 dilution; catalog no. D14E12, Cell Signaling 
Technology), followed by incubation with the appropriate secondary 
antibody (1:100 dilution; Jackson Immunoresearch Laboratory). All 
images were visualized on a Nikon Eclipse microscope and acquired at 
the same exposure with QCapture software.
Real-time PCR. Total RNA from mouse paws was isolated using 
RNeasy Midi Kit (Qiagen Inc.) as recommended by the manufactur-
ers. 2 μg RNA was used to synthesize cDNA by reverse transcription 
using the High Capacity cDNA Reverse Transcriptase kit (Applied 
Biosystems, Life Technologies) on a Multigene thermal cycler system 
(Labnet International Inc.). The reverse transcription product served 
as the template for real-time PCR analysis on a 7500 RT-PCR Sys-
tem (Applied Biosystems) using fluorogenic primers specific for p65 
(PPM04224F, Qiagen Inc.), p100 (PPM03204G, Qiagen Inc.), and 
GAPDH (4352339E, Applied Biosystems) according to the manufac-
turer’s recommendations. Total RNA recovered from p5RHH-p65 
siRNA nanoparticle–treated mice was approximately 20-fold lower 
than controls due to the lack of inflammation/inflammatory cells. Data 
are presented as mRNA expression of target gene relative to Gapdh.
Western blot analysis. Ogran or paw lysates were prepared with 1% 
NP-40 lysis buffer containing proteinase inhibitor cocktail (Sigma-
Aldrich). Briefly, cells or paws were homogenized, sonicated in the 
lysis buffer, and cleared by centrifugation at 18,000 g for 10 minutes 
at 4°C. Protein content was quantified and equivalent amount frac-
tionated by SDS-PAGE under reducing conditions. Membranes were 
blotted with anti-p65, anti-p100/p52, anti-p105/p50, and anti-RelB 
paw thickness was determined daily by dial calipers, and an average 
change in ankle thickness was determined for each mouse from the 
2 hind paw measurements. Mice were also weighed every other day, 
and the percentage of weight loss from baseline was calculated. On 
day 10, mice were sacrificed, and their blood, paws, and organs were 
harvested for analysis.
Histologic analysis. Paws were harvested on day 10, fixed in 10% 
buffered formalin for 48 hours, decalcified in EDTA solution, embed-
ded in paraffin, and sectioned at 5 μm. The sections were stained with 
H&E or toluidine blue. Inflammatory cell influx, bone erosions, and car-
tilage integrity were assessed as previously described (42, 43). Digital 
images of 5 random areas per H&E-stained paw section were acquired 
at ×400 magnification, and the number of exuded inflammatory cells 
was enumerated. The number of bone erosions was enumerated per 
millimeter of bone surface using ImageJ. Proteoglycan content, an 
indication of cartilage integrity, was graded on toluidine blue–stained 
sections on a scale of 0–4 (0, fully stained cartilage; 1, <25% unstained; 
2, 25%–50% unstained; 3, 50%–75% unstained; 4, >75% unstained), as 
previously described (44). Quantitative scoring was performed by an 
observer blinded to the treatments. Each value represents the average 
per animal derived from the cumulative scoring of 2 hind paws.
Immunofluorescence. The frozen sections (9 μm) of harvested paws 
were fixed in 4% paraformaldehyde for 20 minutes at room tempera-
ture, incubated with rat anti-mouse F4/80 (1:100 dilution; catalog 
no. 14-4801, eBioscience), biotinylated rat anti-mouse Mac-3 (1:200 
dilution; catalog no. CL8943AP, Cedarlane Laboratories), or rabbit 
Figure 8. Effects of p5RHH-p65 siRNA nanopar-
ticles on off-target immune cells. Arthritic mice 
were serially treated with HBSS, p5RHH siRNA 
nanoparticles, or p5RHH-p65 siRNA nanoparticles 
on days 4, 5, and 6, and spleens were harvested 
on day 10. (A) Splenocytes were enumerated upon 
harvest at day 10. (B) Splenic immune cell sub-
populations were analyzed by flow cytometry using 
markers specific for T cells (CD4 and CD8), B cells 
(CD19), natural killer cells (NK1.1), and T regulatory 
cells (Foxp3). (C–F) Splenic CD4+ T cells (2 × 105) 
were purified by magnetic beads and activated ex 
vivo on plate-bound anti-CD3 monoclonal antibody 
(5 μg/ml) for 72 hours. The supernatants were 
harvested and assayed for TNF-α (C), IFN-γ (D),  
IL-6 (E), and IL-10 (F) by cytometric bead array. CD4+ 
T cells cultured in medium without anti-CD3 served 
as controls.
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Analysis of splenic subpopulations. Spleens were 
harvested and mechanically dissociated to obtain 
single-cell suspensions. The following antibod-
ies were used: PE-conjugated anti-CD25 (PC61, 
BD Biosciences — Pharmingen), PE-conjugated 
anti-NK1.1 (PK136, eBioscience), FITC- or PerCP-
conjugated anti-CD4 (L3T4, BD Biosciences — 
Pharmingen), FITC-conjugated anti-CD19 (1D3, 
BD Biosciences — Pharmingen), PerCP- or APC-
conjugated anti-CD8 (53-6.7, BD Biosciences — 
Pharmingen). In general, 106 cells were blocked 
with the anti-FcR mAb 2.4G2, stained with the indi-
cated Abs for 20 minutes at 4°C, and then washed 
and resuspended for FACS analysis. Foxp3 expres-
sion was analyzed using the Foxp3 Staining Kit (cat-
alog no. 88-8118-40, eBioscience) according to the 
manufacturer’s instructions. Flow cytometry was 
performed using a BD FACSCalibur. Data analysis 
was performed using BD CellQuest Pro software.
CD4+ T cell purification and stimulation. CD4+ 
T cells were isolated from mouse spleens with 
autoMACS Separator by positive magnetic sorting according to the 
manufacturer’s protocol (MACS CD4+ microbeads; catalog no. 130-
049-201, Miltenyi Biotech). The purity of the isolated CD4+ population 
was verified by surface staining with fluorescently labeled anti-CD4, 
anti-CD8, and anti-CD19 mAbs (BD Biosciences) and flow cytometry. 
Purified CD4+ T cells were resuspended at 2 × 106 cells/ml in RPMI 
1640 supplemented with 10% (v/v) FBS, 1% (v/v) NEAA, 1% (v/v) 
sodium pyruvate, 2 mM l-glutamine, 10 mM HEPES, 50 μM 2-mer-
captoethanol, 100 μg/ml streptomycin, and 100 U/ml penicillin (Sig-
ma-Aldrich), then plated at 2 × 105 cells/well in 96-well flat-bottomed 
microtiter plates coated with 5 μg/ml anti-CD3 mAb (BD Biosciences 
— Pharmingen) and cultured for 72 hours.
After the 72-hour incubation, culture supernatants were harvest-
ed, and cytokine concentrations were determined by BD Cytometric 
Bead Array (CBA) (Mouse Inflammation Kit; catalog no. 552364, BD 
Biosciences) according to the manufacturer’s protocol. Cells were 
harvested and acquired on BD FACSCalibur for 45 seconds. Cell pro-
(1:1,000 dilution; catalog no. 4766S, Cell Signaling Technology) and 
anti-mouse β-actin (1:500 dilution; catalog no. sc-1615, Santa Cruz 
Biotechnology). The blots were washed and incubated with HRP-
conjugated anti-rabbit IgG (1:2,000, Jackson ImmunoResearch Labo-
ratories). Bands were visualized using a SuperSignal Western Blotting 
Kit (Thermo Scientific).
Cytokine analysis. Paws were homogenized in 1 ml PBS, and lysates 
were cleared by centrifugation. TNF-α, IL-6, and MCP-1 concentrations 
in paw lysates were measured by cytometric bead array using the Mouse 
Inflammation Kit (catalog no. 552364, BD Biosciences) according to the 
manufacturer’s recommendations. IL-1β was measured by ELISA (R&D 
Systems) according to the manufacturer’s recommendations.
Hematologic parameters and serum chemistries. Day 10 blood 
was drawn from the inferior vena cava and assayed for wbc counts/
differentials and serum chemistries (hepatic and renal functions). 
Analysis was performed by the Washington University Department 
of Comparative Medicine.
Figure 9. Effects of p5RHH-p65 siRNA nanoparticles 
on immune responses. (A) Naive mice were injected 
with 1 dose of HBSS, p5RHH siRNA nanoparticles, 
or p5RHH-p65 nanoparticles, and their plasma was 
obtained after 30 minutes for C3a assay as evidence 
of complement activation. Mice injected with 50 molar 
percentage of DOTAP (DOTAP NP) served as positive 
controls for robust complement activation. (B and 
C) Arthritic mice were serially treated with HBSS, 
p5RHH siRNA nanoparticles, or p5RHH-p65 siRNA 
nanoparticles on days 4, 5, and 6. On day 10, serum 
was obtained and probed for the presence of IgM 
and IgG antibodies against p5RHH (B) or the p5RHH 
siRNA nanocomplex (C). The levels of specific antibody 
response (measured by direct absorbance at 450 nm) 
were similar in all 3 treatment groups and minimally 
higher than the levels observed in μMT mice that lack 
all antibodies. (D) Total serum levels of IgM and IgG 
were also unchanged after nanoparticle treatment.
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ma diluted 1:100 in reagent diluent) for 1 hour at room temperature. 
Plates were washed 3 times, followed by incubation with biotinylated 
anti-mouse C3a (250 ng/ml) for 1 hour at room temperature. Plates 
were washed, incubated with streptavidin-peroxidase (400 ng/ml; 
Sigma-Aldrich) for 30 minutes, and washed again, after which 100 μl 
peroxide-chromogen solution (R&D Systems) was added to each well, 
and color development was read at 450 nm with a SpectraMax Plus 
reader (Molecular Devices). Mouse recombinant C3a (BD Bioscienc-
es) was used to establish the standard curve.
IVIS imaging. In vivo fluorescence images were acquired and ana-
lyzed with a Xenogen IVIS Spectrum imaging system (Caliper Life- 
Sciences). During image acquisition, mice were maintained under isoflu-
rane inhalation anesthesia. The settings (excitation, 640 nm; emission, 
700 nm; exposure time, 2 s; binning factor, 8; f value, 2; field of view, 12.9) 
were used for image acquisitions at various time points after i.v. injection 
of nanoparticles containing Cy5.5 fluorophore–labeled scrambled siRNA, 
in free form or packaged in nanocomplexes. For the control animals, HBSS 
with Ca2+ and Mg2+ was injected i.v., and images were acquired using the 
same settings as above. The resultant pseudocolor “efficiency image” was 
used to illustrate the paw or organ accumulation of labeled siRNA.
Statistics. Comparisons between groups were performed by 
2-tailed, unpaired t test without correction. Grading data were ana-
lyzed with χ2 test. Comparisons among multiple groups (≥3) were per-
formed by 1-way ANOVA. Equality of variance assumption was tested, 
and Bonferroni’s correction for multiple comparisons was performed. 
Normality assumption appeared to be met, and tests for equality vari-
ance were conducted, revealing no differences. The sample size cho-
sen (number of animals per treatment) was based on means and vari-
ances in similar experiments with various mouse models of arthritis 
for detection of differences between experimental groups at an α level 
of 0.05 and a statistical power of 0.80, assuming a 2-sided test.
Study approval. All animal experiments were performed in com-
pliance with federal laws and in strict accordance with the guidelines 
established by the Division of Comparative Medicine at Washington 
University. The animal protocol is subjected to annual review and 
approval by The Animal Studies Committee of Washington University.
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liferation was analyzed using BD CellQuest Pro software. All assays 
were performed in triplicate.
Immune responses to nanoparticles. Total IgG and IgM were mea-
sured using standard ELISA. Briefly, a 96-well plate was coated with 
goat anti-mouse IgG (Southern Biotechnology Associates Inc.) or goat 
anti-mouse IgM (Southern Biotechnology Associates Inc.) capture anti-
body (1 μg/ml in PBS) and incubated at 4°C overnight. After washing and 
blocking with 1% BSA in PBS, diluted mouse sera (1:40,00–1:400,00 
dilution) were added to wells and incubated at room temperature for 
1 hour. After further washing, 100 μl HRP-conjugated goat anti-mouse 
IgG (Southern Biotechnology Associates Inc.) or goat anti-mouse IgM 
(Southern Biotechnology Associates Inc.) antibody (1:3,000 dilution in 
1% BSA in PBS) were added to the plate and incubated for 2 hours at 
room temperature. After washing, 100 μl peroxide-chromogen solution 
(R&D Systems) was added to each well, and color development was read 
at 450 nm with a SpectraMax Plus reader (Molecular Devices). Purified 
mouse IgG (Jackson ImmunoResearch Laboratories) and IgM (Rock-
land Immunochemicals) were used to establish the standard curves.
To measure IgM- or IgG-specific response to the p5RHH peptide 
or p5RHH siRNA nanocomplexes, 96-well plates (Immunlon 4 HBX; 
Thermo Fisher Scientific Inc.) were incubated with 100 μl/well of 
p5RHH peptide or p5RHH siRNA nanoparticles at a p5RHH peptide 
concentration of 2 μM at 4°C overnight. To determine the amount of 
material that bound to the surface of the wells, unbound p5RHH pep-
tide or p5RHH siRNA nanoparticles were measured using a fluores-
cence spectrofluorometer (Varian Inc.). Since p5RHH contains 1 trypto-
phan residue, tryptophan fluorescence emission spectra (300–500 nm) 
were measured after excitation at 280 nm. Standard curves were gen-
erated, and the amounts of unbound materials were calculated against 
standard curves. For the p5RHH-coated plate, peptide was used at a 
concentration of 2.21 μg/ml. For the p5RHH siRNA–coated plate, the 
peptide was used at a concentration of 3.58 μg/ml. After washing and 
blocking with 1% BSA in PBS, diluted mouse sera (1:10–1:100 dilution) 
were added to wells and incubated for 1 hour at room temperature fol-
lowed by HRP-conjugated goat anti-mouse IgG (Southern Biotechnol-
ogy Associates Inc.) or goat anti-mouse IgM (Southern Biotechnology 
Associates Inc.) antibody as above. Color development was performed 
using peroxide-chromogen solution (R&D Systems) as above. Data are 
presented as direct absorbance (OD at 450 nm).
Off-target nanoparticle uptake. Mice were injected i.v. with 200 
μl HBSS or Cy3-labeled peptide/scrambled RNA-seq nanoparticles. 
Mice were sacrificed after 30 minutes or 2 hours, and both periph-
eral blood wbcs and splenocytes were obtained at each time point for 
analysis of cell-associated Cy3-labeled particles by flow cytometry. 
Cells were also stained with Ly6G (neutrophils), Ly6C (monocytes), 
TCR-β (T cells), and CD19 (B cells) (all BD Biosciences — Pharmin-
gen) to detect specific colocalization.
Complement activation. Mice were injected i.v. with 200 μl of pep-
tide-siRNA nanoparticles. Blood was collected from the inferior vena 
cava at 30 minutes after nanoparticle injection directly into 10-mM 
EDTA tubes to prevent further ex vivo complement activation. Fresh 
plasma was prepared from collected blood for C3a ELISA. Briefly, 
plates were coated overnight at 4°C with rat anti-mouse C3a (4 μg/ml) 
monoclonal antibody (BD Biosciences). After blocking with reagent 
diluent (1% BSA in PBS) for 1 hour at RT, the plates were washed 3 
times with ELISA wash buffer (0.05% [v/v] Tween 20 in PBS) and 
incubated with samples (100 μl of same-day, freshly obtained plas-
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